A juvenile animal study is a nonclinical safety study conducted on animals that have not yet reached full maturity. It is not routinely performed for pharmaceuticals with a paediatric target population; instead, it is considered when data from adult animals, standard nonclinical studies, and existing clinical experience do not allow for an adequate assessment of safety in the relevant developmental phase. In English, it is referred to as a Juvenile Animal Study (JAS).
When a Juvenile Study is Considered
The EMA cites several triggers, including target organ or systemic toxicity related to developing systems, potential effects on growth and development, or pharmacological action on organs undergoing postnatal maturation. Significant differences in pharmacokinetics between young and adult populations, the clarification of a specific concern, and questions regarding reversibility can also justify such a study.
The decision is derived on a case-by-case basis from the entire data package. Relevant factors include identified target organs, exposure margins, differences in exposure at paediatric-relevant doses, as well as the age and treatment duration of the intended paediatric population. A JAS is therefore not an automatic consequence of paediatric development, but a targeted response to a specifically identified safety gap.
Study Design and Animal Welfare
The choice of species, starting age, dosing duration, and endpoints must reflect the maturation phase relevant to the clinical question. Data from adult studies can be utilized to avoid unnecessary duplication. The EMA expects a justification as to why the investigation can provide additional information and how it will be linked to available data.
During planning, the burden must be weighed particularly carefully against the additional knowledge gained. The investigation should only include those endpoints that answer the identified safety question. This prevents a paediatric development program from being burdened by a broad but scientifically untargeted animal study.
Distinction from Regulatory Paediatric Planning
A juvenile animal study is a nonclinical experiment designed to close a safety gap. It is neither a paediatric investigation plan nor an administrative tool for development planning. However, its results can inform regulatory planning if they influence the selection of doses, age groups, or clinical monitoring measures.
In contrast, the Paediatric Investigation Plan describes the regulatory development strategy for children. It does not automatically mandate any single toxicity study. The existing entries for paediatric-investigation-plan and pediatric-investigation-plan address this planning level; the JAS pertains exclusively to the nonclinical investigation in young animals.
ICH S11 reinforces the weight-of-evidence approach: additional nonclinical investigations are only indicated if previous nonclinical and human data do not sufficiently support the paediatric study. A JAS should address questions that cannot be adequately answered by other nonclinical studies or paediatric trials, including potential long-term effects. An in-vitro or ex-vivo approach may be equally appropriate.
If a JAS is conducted, its treatment period and endpoints should be tailored to the identified safety concern and the intended paediatric use. ICH S11 explicitly advises against a design featuring every conceivable additional endpoint without individual justification. Early exchange with authorities can help avoid unnecessary investigations and ensure the validity of the chosen study.
Adult animal data remains an important starting point. A JAS should not merely repeat known toxicity if no increased sensitivity or other developmental concern is plausible. Its value lies in investigating the age-related gap that remains open within the existing safety dataset.
The selection of the starting age is therefore not a formal matter. It must reflect the point in time at which the affected organ or system in the child might be particularly susceptible. Only then can the investigation make a robust contribution to the paediatric safety assessment.
Relevance for clinical trials
If a JAS appears necessary, its design can influence the initiation or expansion of paediatric clinical trials. Findings in growing target organs, statements on reversibility, and exposure comparisons become relevant for age limits, safety laboratory parameters, growth monitoring, or follow-up. Clinical relevance depends significantly on the investigated animal developmental phase matching the intended age of the children.
Full-service CROs like Mediconomics support the linking of nonclinical safety questions with the paediatric clinical strategy, for example through data gap analyses, development of monitoring concepts, and regulatory medical writing. The collaboration of Nonclinical, Paediatrics, Biostatistics, and Clinical Operations can translate JAS results into coherent study documentation.
Frequently Asked Questions (FAQ)
Is a juvenile animal study mandatory for every paediatric medicine?
There is no general obligation. The EMA recommends a case-by-case assessment if existing data does not support a safety evaluation in the intended paediatric age group.
What does the investigation specifically focus on?
It can focus on growth, development, maturing organs, age-dependent exposure, or the reversibility of previously known findings.
Is a JAS part of the Paediatric Investigation Plan?
It can serve as a scientific basis for paediatric development, but it remains a nonclinical study and is not to be equated with the regulatory plan.
Regulatory References
- EMA, Guideline on the need for non-clinical testing in juvenile animals of pharmaceuticals for paediatric indications – describes the triggers and case-by-case assessment of juvenile studies.
- ICH S11, Nonclinical Safety Testing in Support of Development of Paediatric Medicines – complements the international nonclinical perspective for paediatric medicines.